Eli Lilly opened higher at $1,429.91, compared with its previous close of $1,423.80. In the last trading session, the stock traded between $1,419.77 and $1,449.64. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Eli Lilly is now worth
$ 556.02
Giving a profit of
$ 456.02 (456.02%)
Note: Past profits do not guarantee future returns.
Rating from 24 Analysts
Today's Change
+$19.92 (+1.40%)
Day High
$1,449.64
Day Low
$1,419.77
Day Open
$1,429.91
Prev Close
$1,423.80
Volume
14,90,448
1W Return
5.65%
1M Return
22.08%
3M Return
18.28%
6M Return
45.85%
1Y Return
41.85%
Market Cap ($ Mn)
13,58,168
PE Ratio
46.85
PB Ratio
31.94
PEG Ratio
1.29
ROE
104.62%
ROCE
39.76%
EPS (TTM)
$7.24
1 Week
5.65%
1 Month
22.08%
3 Months
18.28%
6 Months
45.85%
9 Months
39.05%
Eli Lilly presents obesity portfolio data at ObesityWeek 2026
Eli Lilly presented data across Zepbound, Foundayo, EloraTZP, and retatrutide at ObesityWeek 2026 (November 14-17, 2026, Washington, D.C.). EloraTZP Phase 2 results showed weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks from an average baseline of 232.4 lbs in adults with obesity or overweight and type 2 diabetes. Retatrutide reduced AHI by up to an average of 36.1 events per hour (60.6%) at 80 weeks in TRIUMPH-1, and by up to an average of 28.4 events per hour (48.1%) in TRIUMPH-2. Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to less than 18 years with obesity at 72 weeks in SURMOUNT-ADOLESCENTS. In the FOUNDERS survey, 96-98% of Foundayo users agreed the pill was simple, convenient, and easy to use.
TodayEli Lilly breaks ground on $3.5bn Pennsylvania obesity drug plant
Eli Lilly broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The site will produce injectable medicines, including the investigational obesity drug retatrutide. The project is expected to create 850 high-wage jobs and approximately 2,000 construction jobs. This investment is part of a broader $50 billion push to expand U.S. medicine production since 2020.
2 days agoLilly Taltz-Zepbound combo shows durable efficacy in psoriatic arthritis
Taltz-Zepbound combo achieved 43.7% ACR50 response vs 15.7% for Taltz alone at Week 52. Composite endpoint (ACR50 + ≥10% weight loss) hit 39.2% in combo arm vs 1.7% in monotherapy. 85.7% of combination patients achieved ≥10% weight reduction compared to 6.7% on Taltz alone. Minimal Disease Activity reached 28.2% in combo arm versus 13.6% for monotherapy at Week 52.
3 days agoEli Lilly, Gilead face near-term drug pricing risks as Washington intensifies scrutiny
Eli Lilly and Gilead face immediate exposure to Medicare price negotiations and Trump's most-favored-nation policy. Fifteen drugs account for $27 billion in Medicare spending, with new prices effective in 2028. Gilead's Biktarvy represents approximately 8% of its 2027 revenue, creating concentration risk. Most other pharma firms have only 0% to 3% of sales exposed to Medicare negotiations. Merck and Bristol Myers face larger pricing tests in 2029 when Keytruda and Opdivo become eligible.
3 days agoLilly's Foundayo cuts sleep apnea severity by 44% in Phase 3 trial
Foundayo reduced apnea-hypopnea index by 43.8% in non-PAP users. Sleep apnea-specific hypoxic burden fell by up to 55.9%. Results presented at AHA Scientific Sessions 2026 and published in JAMA. FDA submission planned for end of 2026 for moderate-to-severe OSA treatment.
5 days agoLilly, Hims & Hers expand access to FDA-approved obesity drugs
Eli Lilly and Hims & Hers partner to distribute FDA-approved obesity drugs via telehealth. Foundayo (oral) costs $149 per month; Zepbound (injectable) costs $299 per month. Patients receive prescriptions from licensed providers on the Hims & Hers platform. Agreement prohibits offering compounded copies of Lilly's GLP-1 medications.
9 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $285.89 | +0.83% | $6,82,520.53M | 43.36 | |
| $295.06 | +0.21% | $5,20,474.53M | 50.69 | |
| $147.72 | +0.52% | $3,62,267.90M | 149.25 | |
| $160.51 | +0.16% | $3,26,079.91M | 30.63 | |
| $184.50 | +0.06% | $2,85,985.36M | 26.09 | |
| $465.65 | -0.30% | $2,52,637.89M | 27.00 | |
| $168.04 | +0.05% | $2,08,314.94M | - | |
| $28.90 | +0.23% | $1,64,326.79M | 41.27 | |
| $41.64 | +2.43% | $1,37,808.70M | 10.50 | |
| $63.42 | +1.77% | $1,27,387.44M | 14.06 | |
| $48.36 | -0.21% | $1,17,057.36M | 24.06 | |
| $50.47 | +1.44% | $1,01,516.65M | 17.60 |
An investment of $100 made 5 years ago in Eli Lilly is now worth
$ 556.02
Giving a profit of
$ 456.02 (456.02%)
Note: Past profits do not guarantee future returns.